Differentiated thyroid cancer presenting initially with distant metastasis.
BACKGROUND
The initial presentation of distant metastases in patients with differentiated thyroid cancer is a rare event. Interestingly, if managed appropriately, the long-term survival in this group of patients is approximately 43%. We intend to review our experience of patients presenting initially with distant metastatic disease in a large series of differentiated thyroid cancer patients.


METHODS
In the entire series of 1,038 consecutive patients treated at Memorial Sloan-Kettering Cancer Center from 1930 to 1985, 44 patients presented initially with distant metastases (4%). There were 22 male and 22 female patients ranging in age from 7 to 75 years with a mean age of 51 years. Patients were analyzed for their prognostic factors, and the survival curves were drawn by the Kaplan-Meier method. Univariate and multivariate analyses were performed by the Cox regression model.


RESULTS
There were 19 patients presenting with distant metastases in 810 patients presenting with papillary thyroid cancer (2.3%). The incidence was high in patients with follicular thyroid cancer (11%). It is interesting to note that the highest incidence of presentation with distant metastatic disease was in patients above the age of 45 and with follicular thyroid carcinoma. The long-term survival in this group is 43% compared with 86% in patients presenting without distant metastasis (P < 0.001). There was no statistical difference in survival of patients below or above the age of 45.


CONCLUSIONS
Even though the presence of distant metastasis at the time of initial presentation in other cancers is considered to be of grave prognosis, for patients with differentiated thyroid cancer, the long-term survival is still 43%. The incidence of distant metastasis is highest in patients with follicular thyroid cancer. Appropriate initial evaluation and treatment will lead to satisfactory long-term survival.
Shaha
A R
AR
Head and Neck Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Shah
J P
JP
Loree
T R
TR
D018263:Adenocarcinoma, Follicular / Q000401:mortality / Q000556:secondary / Q000628:therapy; D000231:Adenocarcinoma, Papillary / Q000401:mortality / Q000556:secondary / Q000628:therapy; D018249:Adenoma, Oxyphilic / Q000401:mortality / Q000556:secondary / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D016019:Survival Analysis; D013964:Thyroid Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D013997:Time Factors; D016896:Treatment Outcome